• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Medicare’s Proposed Coverage for Alzheimer’s Scan Could Be Boon for Eisai/Biogen

cafead

Administrator
Staff member
  • cafead   Jul 18, 2023 at 11:52: AM
via Monday, the Centers for Medicare & Medicaid Services (CMS) is prepared to ease the limits on its coverage of PET scans for detecting amyloid plaques in the brains of patients with Alzheimer’s disease. If the proposed change goes into effect, it could mean better business for Eisai, Biogen and other drugmakers whose new Alzheimer’s treatments require such scans.

article source